// App-Quantinova.ai

493 : Drug response profiling to inform individualized treatment approaches in high risk leukemia

Researchers

Presenter

  • Viktoras Frismantas

Principal Investigators

  • Anna Rinaldi

  • Maria Pamela Dobay

  • Martin Stanulla

  • Andreas E. Kulozik

  • Martina Muckenthaler

  • Cornelia Eckert

  • Thomas Radimerski

  • Salome Higi

  • Sabrina Eugster

  • Blerim Marovca

  • Peter Horvath

  • Mauzro Delorenzi

  • Joachim Kunz

  • Obul R. Bandapalli

  • Gunnar Cario

Medical Centers

  • Swiss Institute of Bioinformatics, Lausanne, Switzerland

  • University Childrens Hospital, Zurich, Switzerland

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Hannover Medical School, Hannover, Germany

  • Synthetic and Systems Biology Unit, Biological Research Center, Szeged, Hungary

Locations

  • Germany

  • Switzerland

  • Hungary

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Topotecan Hydrochloride

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved